Ads
related to: beta thalassemia medications to avoid alcohol- Managing Thalassemia
There's hope for managing the
symptoms & complications.
- About Thalassemia
Find more information on
thalassemia & how to manage.
- Healthcare Professionals
Please visit this website if
you are a healthcare professional.
- Thalassemia Support
Connect with a Clinical Nurse
Educator for support.
- Managing Thalassemia
Search results
Results From The WOW.Com Content Network
Patients with beta thalassemia minor are usually asymptomatic and are often monitored without treatment. [8] Beta thalassemia minor may coexist with other conditions such as chronic hepatitis B, chronic hepatitis C, non-alcoholic fatty liver disease and alcoholic liver disease that, when combined or co-existing, may cause a person to have iron ...
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [33] It was approved for medical use in the European Union in May 2019, [34] and in the United States in August 2022.
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [8]
“It’s a growing problem. Alcohol is a very simple molecule with very diverse effects on physiology,” explains White. “There aren’t many things the body does that alcohol doesn’t impact.”
Alpha thalassemia is caused by deficient production of the alpha globin component of hemoglobin, while beta thalassemia is a deficiency in the beta globin component. [7] The severity of alpha and beta thalassemia depends on how many of the four genes for alpha globin or two genes for beta globin are faulty. [2]
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [1] [5] [2] It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.
For premium support please call: 800-290-4726 more ways to reach us
The treatment was approved in the United Kingdom for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in November 2023. [10] [11] [12] It was approved in the United States for the treatment of sickle cell disease in December 2023 and for the treatment of transfusion-dependent beta thalassemia in January 2024. [13 ...
Ad
related to: beta thalassemia medications to avoid alcohol